Hereditary hemochromatosis (HH) is classically associated with a Cys282Tyr (C282Y) mutation of the HFE gene. Non-C282Y HH is a heterogeneous group accounting for 15% of HH in Northern Europe. Pathogenic mutations of the transferrin receptor 2(TfR2) gene have been identified in 4 Italian pedigrees with the latter syndrome. The goal of this study was to perform a mutational analysis of the TfR2 and HFE genes in a cohort of non-C282Y iron overload patients of mixed ethnic backgrounds. Several sequence variants were identified within theTfR2 gene, including a homozygous missense change in exon 17, c2069 A→C, which changes a glutamine to a proline residue at position 690. This putative mutation was found in a severely affected Portuguese man and 2 family members with the same genotype. In summary, pathologic TfR2 mutations are present outside of Italy, accounting for a small proportion of non-C282Y HH.

In 1996, Feder et al1 identified 85% of hereditary hemochromatosis (HH) patients of Northern European descent as being carriers of a C282Y mutation in the HFEgene. Since 1996, several other mutations of the HFEgene have been identified in association with HH2-4; however, with rare exception, these mutations occur in tandem with trans C282Y mutations and are infrequent causes of HH.

Mutations of the transferrin receptor 2 (TfR2) gene have been implicated as the genetic basis of a novel autosomal recessive adult-onset HH syndrome in 4 Italian pedigrees (Hemochromatosis, Type 3, OMIM 604250).5,6 The TfR2α transcript is a homolog of the transferrin receptor (TfR1) protein with 48% identity and 66% similarity in the extracellular portion of the protein.7TfR2 has both similar and distinct functional properties from TfR1, including a common affinity for diferric transferrin7 and a lack of affinity for the HFE protein,8 respectively. Nonsense or nonfunctional mutations of TfR2 are associated with HH5,6; however, the frequency and physiologic basis of this association are unclear.

The goal of the current study was to identify a genetic basis for iron overload in a cohort of patients with non-C282Y iron overload by direct sequencing of both the TfR2 and the HFE genes.

The study population consisted of all patients referred to the Molecular Diagnostic Laboratory of Children and Women's Health Centre in Vancouver, BC, Canada, for genetic testing for HH prior to May 5, 2000. From this database, we selected all patients with a transferrin saturation greater than or equal to 60%, an elevated serum ferritin level, and a negative test result for the C282Y HFE mutation. From the same laboratory, 93 control samples were obtained.

Testing for the HFE C282Y mutation was performed according to standard methods. Polymerase chain reaction (PCR) amplification and direct sequencing of all coding regions and all intron/exon boundaries of the HFE and TfR2 genes were performed on each patient at the British Columbia Genome Sequencing Centre (BCGSC).

Method details are available in the supplementary information stored on the BCGSC website (www.bcgsc.bc.ca/fg/hemoc). The project received approval from the ethical review boards of all participating institutions. Investigations were undertaken with the informed consent of all study participants.

HFE and TfR2 sequencing was performed on DNA from 89 patients of mixed ethnic origin (patient demographic data available in the supplementary information). Of these patients, 15 had risk factors for secondary iron overload. Among this cohort, one probable pathogenic mutation of the TfR2 gene was identified, c2069 A→C, Q690P (Figure1). This novel mutation occurred in a single patient who was a child of a consanguineous marriage (Figure 2). The remaining patients either did not have a TfR2 or HFE genotype suggestive of HH (n = 74) or had genotypes associated with normal or mild iron overload status (HFE H63D/H63D, n = 11; HFE H63D/S65C, n = 3).9-11 In addition, 18 TfR2polymorphisms were identified, including 3 novel and one previously described12 amino acid coding changes (Figure 1 andwww.bcgsc.bc.ca/fg/hemoc). Five HFE single nucleotide polymorphisms were identified (www.bcgsc.bc.ca/fg/hemoc).

Fig. 1.

Summary of new and previously described coding sequence changes of the

TfR2 gene. Text box color code is as follows: purple indicates previously described homozygous mutations, white indicates a novel homozygous mutation, and orange indicates heterozygous sequence changes. The asterisk indicates a previously described heterozygous sequence change. For each sequence change identified in this study, both the amino acid (above) and cDNA nucleotide (below) changes are indicated.

Fig. 1.

Summary of new and previously described coding sequence changes of the

TfR2 gene. Text box color code is as follows: purple indicates previously described homozygous mutations, white indicates a novel homozygous mutation, and orange indicates heterozygous sequence changes. The asterisk indicates a previously described heterozygous sequence change. For each sequence change identified in this study, both the amino acid (above) and cDNA nucleotide (below) changes are indicated.

Close modal
Fig. 2.

Q690P pedigree.

Age (A, years), ferritin (F, μg/L), transferrin saturation (S, %), and TfR2 Q690P and HFE H63D mutation status for the Portuguese family. “+” indicates the presence of the mutant allele, and “−” indicates its absence. The mother was heterozygous for both TfR2 Q690P and HFE H63D. Abnormal results are indicated in bold type. Values listed are those of the initial assessment for each patient.

Fig. 2.

Q690P pedigree.

Age (A, years), ferritin (F, μg/L), transferrin saturation (S, %), and TfR2 Q690P and HFE H63D mutation status for the Portuguese family. “+” indicates the presence of the mutant allele, and “−” indicates its absence. The mother was heterozygous for both TfR2 Q690P and HFE H63D. Abnormal results are indicated in bold type. Values listed are those of the initial assessment for each patient.

Close modal

With respect to HFE mutations, a high percentage of patients carried the HFE H63D allele (48 of 89; 54%). This value is above that expected as compared to carrier rates for H63D ranging from 12% to 37% in European population studies.13 This overrepresentation of HFE H63D genotypes is in keeping with the hypothesis that HFE H63D mutations contribute to an iron overload phenotype, even in the absence of the HFE C282Y allele.14,15 

The TfR2 Q690P mutation was identified in an individual of Portuguese descent. He presented at 29 years of age with fatigue, hypogonadotropic hypogonadism, hyperpigmentation, mild elevation of liver transaminases, and idiopathic thrombocytopenic purpura. He had markedly elevated serum iron indices (Figure 2) and has had more than 12 g of iron removed via phlebotomy in the past 4 years. Additional hematologic abnormalities included mild normocytic anemia and lymphopenia. He is heterozygous for the HFE H63D mutation. The Q690P mutation was not identified in our control group, 20 Portuguese controls, and 39 Portuguese patients with nonclassical HH.

The family of the Q690P proband was investigated for iron overload and the presence of the TfR2 Q690P mutation. The results of the family study are summarized in Figure 2 (additional data available atwww.bcgsc.bc.ca/fg/hemoc). Biochemical evidence of iron overload was detected in 2 female siblings (IV-3 and IV-4 in Figure 2), both of whom are homozygous for the TfR2 Q690P mutation. They had no clinical manifestations of disease aside from arthralgia, which affected sibling IV-3. Sibling IV-3 had a transferrin saturation level measured at greater than 100% with a normal serum ferritin and no evidence of hepatic iron overload as assessed by magnetic resonance imaging.16 Her hematologic profile revealed neutropenia but was otherwise normal. She has a wild-type HFE genotype. Sibling IV-4 had a transferrin saturation value of 77% and elevations of serum ferritin and hepatic iron stores (263 μmol/g). Her hematologic profile revealed a mild normocytic anemia and lymphopenia. She is heterozygous for the HFE H63D mutation. Sibling IV-1 and the mother of the proband showed no evidence of an iron overload phenotype or hematologic abnormalities. The mother is heterozygous for the TfR2 Q690P allele, while sibling IV-1 is wild type.

The impact of the Q690P mutation on TfR2 function can be estimated by analysis of the corresponding position in the homologous TfR1 protein (threonine 658). TfR1 thr658 is residue 18 of 23 amino acids forming the α helix 3 of the helical domain in the extracellular component of the protein.17 Sixteen of the 23 amino acids are identical or structurally conserved between TfR1 and TfR2.17 In TfR1, this α helix forms the proposed binding sites for both diferric transferrin and HFE.17,18 Specifically, mutagenesis of TfR1 α helix 3 amino acids 643, 646–648, and 650 all yield TfR1 proteins with significantly reduced affinity for transferrin.18,19 Therefore, disruption of the α helix 3 secondary structure via insertion of a proline residue at position 690 in TfR2 (position 658 in TfR1) would be expected to disrupt a key binding site for diferric transferrin. This loss of function could then manifest as an iron overload phenotype similar to that associated withTfR2 nonsense mutations.

The strong clinical expression of HH in the proband and family members with the Q690P homozygous mutation suggest that the TfR2 interaction with transferrin plays a critical role in normal iron homeostasis. However, because TfR2 is primarily expressed in hepatocytes and in erythroid precursors,20 much remains to be elucidated as to how an abnormal interaction with the transferrin protein results in systemic iron overload.

In our cohort of non-C282Y HH patients of predominately mixed European descent, only 1 of 89 was found to have a novel pathogenic mutation of either the TfR2 or HFE genes. The isolated nature of this finding is concordant with previous studies ofTfR212,21,22 orHFE15 23 in non-C282Y homozygous HH. However, the identification of the TfR2 Q690P mutation helps to establishTfR2 mutations as infrequent but important contributors to autosomal recessive adult-onset HH. This patient's family is the firstTfR2-associated HH pedigree to be described outside Italy.

We give special thanks to Duane Smailus and the Genome Sequencing Centre sequencing team for providing extensive technical support in this sequencing project. We also thank Dr Doug Horsman from the British Columbia Cancer Agency for his critical review of this manuscript. Most important, we thank the patients and family members for agreeing to participate in this study.

Prepublished online as Blood First Edition Paper, April 17, 2002; DOI 10.1182/blood-2002-01-0133.

Supported by a fellowship grant from the National Science and Energy Research Council (NSERC) of Canada (G.V.).

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Feder
 
JN
Gnirke
 
A
Thomas
 
W
et al
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.
Nat Genet.
13
1996
399
408
2
de Villiers
 
JN
Hillermann
 
R
Loubser
 
L
Kotze
 
MJ
Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria.
Hum Mol Genet.
8
1999
1517
1522
3
Pointon
 
JJ
Wallace
 
D
Merryweather-Clarke
 
AT
Robson
 
KJ
Uncommon mutations and polymorphisms in the hemochromatosis gene.
Genet Test.
4
2000
151
161
4
Mura
 
C
Raguenes
 
O
Ferec
 
C
HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in a mild form of hemochromatosis.
Blood.
93
1999
2502
2505
5
Camaschella
 
C
Roetto
 
A
Cali
 
A
et al
The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.
Nat Genet.
25
2000
14
15
6
Roetto
 
A
Totaro
 
A
Piperno
 
A
et al
New mutations inactivating transferrin receptor 2 in hemochromatosis type 3.
Blood.
97
2001
2555
2560
7
Kawabata
 
H
Yang
 
R
Hirama
 
T
et al
Molecular cloning of transferrin receptor 2: a new member of the transferrin receptor-like family.
J Biol Chem.
274
1999
20826
20832
8
West
 
AP
Bennett
 
MJ
Sellers
 
VM
Andrews
 
NC
Enns
 
CA
Bjorkman
 
PJ
Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE.
J Biol Chem.
275
2000
38135
38138
9
Beutler
 
E
Felitti
 
V
Gelbart
 
T
Ho
 
N
The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic.
Ann Intern Med.
133
2000
329
337
10
Whitfield
 
JB
Cullen
 
LM
Jazwinska
 
EC
et al
Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins.
Am J Hum Genet.
66
2000
1246
1258
11
Gochee
 
PA
Powell
 
LW
Cullen
 
DJ
Du Sart
 
D
Rossi
 
E
Olynyk
 
JK
A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation.
Gastroenterology.
122
2002
646
651
12
Lee
 
PL
Halloran
 
C
West
 
C
Beutler
 
E
Mutation analysis of the transferrin receptor-2 gene in patients with iron overload.
Blood Cells Mol Dis.
27
2001
285
289
13
Hanson
 
EH
Imperatore
 
G
Burke
 
W
HFE gene and hereditary hemochromatosis; a HuGE review: human genome epidemiology.
Am J Epidemiol.
154
2001
193
206
14
Mura
 
C
Le Gac
 
G
Raguenes
 
O
Mercier
 
AY
Le Guen
 
A
Ferec
 
C
Relation between HFE mutations and mild iron-overload expression.
Mol Genet Metab.
69
2000
295
301
15
Aguilar-Martinez
 
P
Bismuth
 
M
Picot
 
MC
et al
Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause?
Gut.
48
2001
836
842
16
Gandon
 
Y
Guyader
 
D
Heautot
 
JF
et al
Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging.
Radiology.
193
1994
533
538
17
Bennett
 
MJ
Lebron
 
JA
Bjorkman
 
PJ
Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor.
Nature.
403
2000
46
53
18
West
 
AP
Giannetti
 
AM
Herr
 
AB
et al
Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites.
J Mol Biol.
313
2001
385
397
19
Dubljevic
 
V
Sali
 
A
Goding
 
JW
A conserved RGD (Arg-Gly-Asp) motif in the transferrin receptor is required for binding to transferrin.
Biochem J.
341
1999
11
14
20
Kawabata
 
H
Nakamaki
 
T
Ikonomi
 
P
Smith
 
RD
Germain
 
RS
Koeffler
 
HP
Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells.
Blood.
98
2001
2714
2719
21
Barton
 
EH
West
 
PA
Rivers
 
CA
Barton
 
JC
Acton
 
RT
Transferrin receptor-2 (TFR2) mutation Y250X in Alabama Caucasian and African American subjects with and without primary iron overload.
Blood Cells Mol Dis.
27
2001
279
284
22
Aguilar-Martinez
 
P
Esculie-Coste
 
C
Bismuth
 
M
Giansily-Blaizot
 
M
Larrey
 
D
Schved
 
JF
Transferrin receptor-2 gene and non-C282Y homozygous patients with hemochromatosis.
Blood Cells Mol Dis.
27
2001
290
293
23
Douabin
 
V
Moirand
 
R
Jouanolle
 
A
et al
Polymorphisms in the HFE gene.
Hum Hered.
49
1999
21
26

Author notes

Gillian Lockitch, Dept of Pathology and Laboratory Medicine, Children's and Women's Health Centre of BC, 4480 Oak St, Vancouver, British Columbia, Canada, V6H 3V4; e-mail:glockitch@cw.bc.ca. In Europe: Maria De Sousa, Laboratory of Molecular Immunology, Institute for Molecular and Cell Biology, Rua do Campo Alegre, 823, 4150-180 Porto, Portugal; e-mail: mdesousa@ibmc.up.pt.

Sign in via your Institution